Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) | MicrobiomeTrials← Back to trialsNCT03109288
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2017-08-11Est. Completion: 2027-01-01
Enrollment target: 250 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Multiple Sclerosis
The proposed study is a parallel-group randomized controlled trial (RCT) designed to establish the behavioral mechanism …
Chicago, United StatesEst. completion Oct 1, 2028
Multiple Sclerosis (MS) Primary Progressive
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicente…
Pheonix, United StatesEst. completion Jun 2030
Recruiting
Lennox Gastaut SyndromeDravet SyndromeTuberous Sclerosis Complex
This study will monitor for potential chronic liver injury and liver fibrosis, in participants treated with cannabidiol …
Little Rock, United StatesEst. completion Aug 1, 2027